Products from BPS Bioscience require a minimum order value above 400€
Applications: This kit is useful for screening for inhibitors of the interaction between SARS-CoV-2 Spike S1 (B.1.617.1) and human ACE2.
Background: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer some protection against the viral infection.A variant called B.1.617.1 (also known as the Kappa variant) was identified in India in the spring of 2021. This variant has a number of mutations in the Spike protein (G142D, E154K, L452R, E484Q, D614G, P681R) that may allow the virus to spread more easily and quickly than other variants.
Description: The Spike S1 (B.1.617.1; Kappa Variant) (SARS-CoV-2): ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between Spike S1 (B.1.617.1) (SARS-CoV-2) and human ACE2 in a homogeneous 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, and the dye-labeled acceptor for one hour. Then the TR-FRET signal is measured using a fluorescence reader capable of measuring Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET).
Storage Stability: This assay kit will perform optimally for up to 6 months from date of receipt when the materials are stored as directed.
Supplied As: Homogeneous 384 reaction format
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. Hoffmann, M. et al. Cell, 181:1-10
2. Yan, R. et al. 2020. Science 367(6485):1444-1448
English
Deutsch
